• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Antipsychotics Review Programs

    Antipsychotics are FDA approved for a variety of diagnoses including but not limited to: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression (as adjunct treatment) and Autistic Disorder (to treat associated irritability). However, there are situations in which a clinician may prescribe an antipsychotic “off-label".​

    In the public and health care arena concerns have been raised, not only about the “off-label" prescribing, but also about the lack of side effect (including weight, body mass index and blood glucose and lipid levels) monitoring of antipsychotics.

    Federally, a Government Accountability Office (GAO) report has outlined concerns about antipsychotic use in Medicaid recipients in Foster Care.

    Published guidelines addressing some of the above issues include, but are not limited to, the American Academy of Child and Adolescent Psychiatry Practice Parameters for Atypical Antipsychotics  and The American Diabetes Association/American Psychiatric Association consensus statement issued in 2004 recommending monitoring body mass index and blood glucose and blood lipid levels on patients taking atypical antipsychotics.

    To support providers who prescribe this drug class, the Office of Pharmacy Services (OPS) has established two programs.

    • Peer Review Program (PRP)
    • Tier 2 & Non-Preferred Antipsychotic Review Program

    Peer Review Program (PRP)

    This program was established to address concerns that an increasing number of children are being prescribed antipsychotics and there is a lack of laboratory monitoring of those children.  The goal of the program is to ensure that children and adolescents receive optimal treatment in conjunction with appropriate non-pharmacologic measures in the safest manner possible. (https://mmcp.dhmh.maryland.gov/pap/docs/Antipsychotic-Peer-review-Project-Narrative.pdf)

    This program began in October 2011 and initially addressed the use of antipsychotics in Medicaid patients under five years of age. In July 2012, it expanded to encompass children under 10 years of age. In January 2014, the program expanded to include any Medicaid recipient 17 years or younger who is prescribed any antipsychotic.

    The program works in partnership with the Mental Hygiene Administration (MHA) and the University of Maryland (UMD) School of Pharmacy and Division of Child and Adolescent Psychiatry. OPS and MHA hosted a webinar to discuss the PRP and answer questions regarding this program on September 15, 2011.​

    For QUESTIONS regarding this program:

    Recipients call 1 (800)492-5231   Option 3

    Providers call 1 (855)283-0876


    Transmittals:#196 – PRP admits < 5 year olds​
    #197 – PRP expands to include

    #198 – PRP expands to include 10 to 17 year olds
    Advisories:     #115 – PRP expands to include youth up to age 10 years
    #122 – No PA Required for Abilify for ages 10 - 17

    #134 – Expansion of Peer Review Program ages 0 to 17

    Tier 2 & Non-Preferred Antipsychotic Review Program

    This program was launched in September 2012. It was designed to address a variety of concerns, including the off-label use of antipsychotics. The goal of the program is to have prescribers, whenever appropriate, prescribe antipsychotics using FDA guidelines for diagnosis, dose and frequency in the most cost-effective manner. 

    To meet this goal, the program has established a prior authorization (PA) process. As always, a PREFERRED antipsychotic (see Preferred Drug List) does not require a prior authorization, if prescribed within the FDA Guidelines for the dose and frequency. Clinical criteria have been established which must be met before a Tier 2 & Non-Preferred (Tier 2 & NP) antipsychotic is approved (see Clinical Criteria​). When seeking a PA for a Tier 2 or NP antipsychotic, remember that it could take up to 1 business day after all requested information is received before a decision is rendered. 

    For QUESTIONS regarding this program:

    Recipients call 1(800)492-5231 Option 3

    Providers call 1(800)932-3918


    Advisories:     #117 – PA for Tier 2 & NP Antipsychotic Medications